2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Computational Biology, Emerging Technologies, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Gene Therapy, Non-Biological Therapies, Women’s Health, Adverse Events, Artificial Intelligence (AI), Biological Processes, Pathogenesis, Microbiome, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality of Care, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Infectious Diseases, Viral, Bacterial, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

2934 Tranexamic acid for heavy menstrual bleeding in adolescents and young adults with sickle cell disease: Safety and clinical outcomes

Julia Jones, BS, Gianna Valenti, MD2, Aditi Kamdar, MD3, Oluwaseun Kemi O Olaiya, DO4
1 Baylor College of Medicine/ Texas Children's Hospital, Houston, United States
2 Children's Hospital of Michigan, Detroit, United States
3 Baylor College of Medicine/ Texas Children's Hospital, Houston, United States
4 Baylor College of Medicine/ Texas Children's Hospital, Houston, United States

Background:

Adolescent females with sickle cell disease (SCD) frequently experience heavy menstrual bleeding (HMB), affecting approximately 32%- 40% of patients. HMB and abnormal uterine bleeding (AUB) can significantly impact quality of life and exacerbate anemia. Tranexamic acid (TXA), an antifibrinolytic agent approved and widely used for the treatment of HMB, effectively reduces bleeding. However, its safety and efficacy have not been studied in patients with SCD, and patients with increased thrombotic risk have been underrepresented in clinical trials.  Although few case reports have described successful TXA use in SCD for hematuria, perioperative management, and intracranial hemorrhage, its use for HMB or AUB in this population has not been systematically evaluated or previously described.

Objective:
To describe the clinical outcomes and adverse events among adolescents and young adults with sickle cell disease treated with tranexamic acid for the management of heavy menstrual bleeding and abnormal uterine bleeding at Texas Children's Hospital.

Methods:
This single-center retrospective case series included postmenarchal patients aged 14–22 years with confirmed SCD who received TXA for HMB or AUB at either pediatric and adolescent gynecology or pediatric hematology clinics between January 2020 and January 2026. Patients were identified using ICD-10 codes, with diagnosis and eligibility confirmed through electronic medical record review. HMB was defined by clinician documentation. Demographic, clinical, and treatment characteristics, including disease-modifying therapy, were collected. Patients with active thrombosis, concurrent anticoagulation therapy, or malignancy were excluded. Outcomes included clinician-documented improvement in bleeding symptoms, the need for additional interventions, thrombotic events, and other adverse events following TXA exposure. Descriptive analyses were performed. Institutional Review Board approval was obtained through Baylor College of Medicine.

Results:
Six adolescents and young adults with sickle cell disease were included in the case series, with a median age of 17.5 years (IQR, 16–21). Genotypes included HbSS (n=2), HbSC (n=3), and HbSβ°-thalassemia (n=1). Among the four patients who underwent menstrual blood loss assessment (66.7%), 50.0%(n=2) reported menses lasting >7 days with menstrual product changes every <2 hours, and 50.0%(n=2) reported menses lasting >7 days with product changes more than once hourly. TXA was prescribed at 1300mg orally three times daily for a maximum of 5 days per menstrual cycle in all patients. Concurrent therapies included hormonal treatment (n=3), iron supplementation (n=3), hydroxyurea (n=4), crizanlizumab (n=1), and a clinical trial drug (n=1). No thromboembolic events, seizures or vision changes were documented following initiation of TXA. Clinician-documented improvement in menstrual bleeding occurred in four patients (66.7%) based on patient reported reduction in menstrual cycle duration and/or menstrual product usage. One patient experienced mild nausea and vomiting. At the last follow-up (median 124.5 days), four patients (66.7%) remained adherent to TXA, and three (50.0%) continued long-term therapy. Documented reasons for discontinuation of TXA included adverse effects (n=1), nonadherence (n=1), and initiation of alternative therapy (n=1). Median hemoglobin prior to treatment was 9.72 g/dL (range, 7.6–10.7 g/dL) and 10.01 g/dL (range, 7.7–11.9 g/dL) at follow-up. Iron studies were only available for one patient prior to TXA initiation, whose ferritin increased from 9 to 11 ng/mL after the initiation of TXA. 

Conclusion:

In this single-center retrospective case series, TXA was used for management of HMB in adolescents and young adults with SCD with clinician-documented improvement in bleeding and no observed thrombotic complications or serious adverse events. Iron status was infrequently assessed, highlighting an important gap in care. Limitations include small sample size, retrospective design, reliance on clinician-document outcomes, and variable follow up duration. These findings support the need for further prospective and multicenter studies to better characterize the safety and effectiveness of TXA in this unique population.

Julia Jones, BS: No relevant conflicts of interest to declare.